Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer’s agitation medications.
A study conducted by researchers from Johns Hopkins University School of Medicine and Tufts University School of Medicine found that a pill form of dronabinol, an FDA-approved synthetic version of THC (the main ingredient in marijuana), reduces agitation in Alzheimer’s patients by an average of 30%.
The researchers say that compared to current treatments for agitation, such as antipsychotics, dronabinol produced similar calming effects without adverse results such as delirium or seizures.
Results of the eight-year clinical trial were presented at the International Psychogeriatric Association conference in Buenos Aires, Argentina, on Sept. 26.“These new findings represent eight years of work dedicated to people who have Alzheimer’s as well as their caregivers,” says Paul Rosenberg, M.D., professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine and co-principal investigator for this study. “Agitation is one of the most distressing symptoms of Alzheimer’s dementia, and we are pleased to make positive strides forward in the treatment of these patients.”
Alzheimer’s Agitation and the Need for New Treatments
Alzheimer’s disease is the most common neurodegenerative disease in the United States, with an estimated 6.7 million cases in Americans age 65 and older, according to the National Institutes of Health. This number is predicted to grow to 13.8 million by 2060. Agitation is difficult to manage. It is defined as excess motor activity (pacing or repetitive movements), verbal aggression, and/or physical aggression. An estimated 40% of people with Alzheimer’s develop agitation.
Although mild agitation can sometimes be moderated by behavioral intervention, in moderate to severe cases, some form of medication is typically required to manage symptoms and provide relief for caregivers.“It is the agitation, not the memory loss, that often drives individuals with dementia to the emergency department and long-term-care facilities,” says Brent Forester, M.D., psychiatrist-in-chief and chairman of the Department of Psychiatry at Tufts Medical Center and co-principal investigator on the study. “Dronabinol has the potential to both reduce health care costs and make an important, positive impact on caregivers’ mental and physical health.”
In the new study, researchers recruited 75 patients with severe Alzheimer’s agitation across five clinical sites, including 35 admitted to The Johns Hopkins Hospital between March 2017 and May 2024. To qualify, patients had to have a formal clinical diagnosis of Alzheimer’s disease and show at least one major symptom of agitation for at least two weeks. Prior to treatment, patients were tested for agitation using the Pittsburgh Agitation Scale (PAS) and the Neuropsychiatric Inventory Agitation/Aggression subscale (NPI-C).
The PAS scores agitation from 0 to 4, with 4 being the most agitated. The NPI-C provides a brief assessment of neuropsychiatric symptoms including delusions, hallucinations, anxiety/depression, and other factors. Baseline scores were acquired from caregivers at the onset of the trial.
Participants were then randomly selected to get either 5 milligrams of dronabinol in pill form or a placebo in pill form twice daily for three weeks, and then retested using the PAS and NPI-C.
Future Research and Cautions
Results from the dronabinol group show an average PAS starting value of 9.68 and an end value of 7.26 after three weeks, a 30% decrease compared to the scores in the placebo group which did not change. Additionally, dronabinol was well tolerated by patients compared to current treatments for agitation.“Results like this are encouraging. We are thrilled that FDA-approved dronabinol was robustly effective and appeared safe for treatment of agitation,” says Rosenberg. “This adds another tool in our efforts to improve the care of our loved ones with Alzheimer’s disease.”
The researchers say they plan longer-term studies of dronabinol for Alzheimer’s disease, as well as expanded sample sizes. They also hope to continue to explore other ways medical cannabis can benefit both patients and caregivers.
Dronabinol is a synthetic form of THC, the psychoactive main ingredient in cannabis (marijuana). The drug was approved by the U.S. Food and Drug Administration in 1985 to treat loss of appetite in patients with HIV/AIDS, and is currently prescribed to treat nausea and vomiting in those undergoing cancer chemotherapy.
The investigators caution that their current study results are not intended to encourage or inform the use of other forms of medical marijuana available in 38 states and the District of Columbia.
Meeting: International Psychogeriatric Association conference
Co-investigators include Halima Amjad, Haroon Burhanullah and Milap Nowrangi at the Johns Hopkins University School of Medicine, Marc Agronin at Miami Jewish Health, and James Wilkins and David Harper at McLean Hospital.
The study was funded by a grant from the National Institute of Aging at the National Institutes of Health.
News
NIH Scientists Discover Gene Responsible for Rare Eye Disease
Findings supported by the NIH pave the way for the development of genetic testing, clinical trials, and therapies. Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a gene linked to certain [...]
Alzheimer’s Breakthrough: Synthetic THC Pill Proves Effective in Clinical Trial
Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer’s agitation medications. A study conducted by researchers from Johns Hopkins University School of Medicine and Tufts University School of Medicine found that a pill form [...]
The Future of Rare Disease Treatment with Precision Medicine
Understanding rare diseases Rare diseases affect less than 5 people out of 10,000. However, this still amounts to about 7% of the world’s population, with over 10,000 such conditions. Almost all are genetic in [...]
Doctors issue warning for upcoming ‘tripledemic
The term ‘tripledemic’ has hit headlines this week as the NHS begins its Covid and fluvaccine roll-out for vulnerable adults. As the cold weather sets in, many of us have experienced a decline in health, and this may [...]
The FDA approved a gel that can stop bleeding from wounds in seconds
Aug 15 (Reuters) - The U.S. Food and Drug Administration has cleared Cresilon's gel to quickly control bleeding, the privately held company said on Thursday, potentially giving emergency medical technicians and combat medics a [...]
High levels of microplastics found in prostate tumors, possibly linked to take-out food
The presence of microplastics in prostate tumors points to potential health risks, and researchers are calling for urgent studies to explore how take-out food may be driving this exposure. In a recent study published [...]
AI outperforms radiologists in brain tumor diagnosis
As artificial intelligence advances, its uses and capabilities in real-world applications continue to reach new heights that may even surpass human expertise. In the field of radiology, where a correct diagnosis is crucial to ensure [...]
Breakthrough Study Reveals Molecular Clues to Dementia Origins
Work could lead to the discovery of new therapeutic targets. For the first time, researchers have identified “molecular markers” linked to degeneration—detectable changes in cells and their gene-regulating networks—that are common across several types [...]
Better than blood tests? Nanoparticle potential found for assessing kidneys
In a study published July 29 in Advanced Materials, University of Texas at Dallas researchers found that X-rays of the kidneys using gold nanoparticles as a contrast agent might be more accurate in detecting kidney [...]
Greener nanomaterials could transform how our everyday stuff is made
Tiny nanoparticles are at the forefront of materials science—with special properties that make them great at absorbing light in solar panels, cleaning wastewater, and delivering drugs precisely. Some nanoparticles take the form of sheets or fibers. But nanomaterials all [...]
AI could predict breast cancer risk via ‘zombie cells’
Women worldwide could see better treatment with new AI technology, which enables better detection of damaged cells and more precisely predicts the risk of getting breast cancer, shows new research from the [...]
Through the eyes of a cat – biomimicry of feline eyes may revolutionize robotic vision
In a recent study published in the journal Science Advances, researchers leveraged crucial aspects of feline eyes, particularly their tapetum lucidum and vertically elongated pupils (VP), to develop a monocular artificial vision system capable of [...]
New Alzheimer’s Therapy Shows Remarkable Results in Animal Trials
A study from TUM demonstrates a promising therapeutic approach. Researchers at the Technical University of Munich (TUM) have made promising advances in preventing Alzheimer’s by developing a new therapeutic strategy. Their approach focuses on targeting the amyloid beta [...]
Rewriting Cancer’s Blueprint: New Study Challenges Old Theories
A new study argues for a revised clonal evolution model of cancer, incorporating genetic and non-genetic factors to improve understanding and treatment. Like all living organisms, cancer cells are driven by the fundamental need [...]
Microplastics Everywhere: Experts Demand Worldwide Treaty Before It’s Too Late
A new report calls for global action on plastic pollution, urging reductions in plastic production and microplastic emissions. Researchers stress the importance of addressing plastic pollution through both scientific and social science perspectives. A [...]
Blood tests could soon predict your risk of Alzheimer’s
Scientists are closing in on biomarkers that reflect the progression of Alzheimer’s disease and could improve treatments. Like many Alzheimer’s researchers, neurologist Randall Bateman is not prone to effusiveness, having endured disappointments in his [...]